Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer

Virchows Archiv

Volumn 460, Issue 6, 2012, Pages 601-609

  Oh, Mee Hye ^a   Lee, Hyun Ju ^a   Yoo, Seol Bong ^b   Xu, Xianhua ^b   Choi, Jae Sung ^a   Kim, Yong Hoon ^a   Lee, Seok Yeol ^a   Lee, Choon Taek ^b   Jheon, Sanghoon ^b   Chung, Jin Haeng ^b  

^a Soonchunhyang University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

MTOR; Non small cell lung cancer; PAkt; Prognosis

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B;

ADULT; AGED; AGING; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84863983858     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1239-6     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
2. Tsuchiya T, Akamine S, Muraoka M et al (2007) Stage IA nonsmall cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 56:341-348 (Pubitemid 46679089)
3. Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719-727 (Pubitemid 44283661)
4. Wakelee H, Dubey S, Gandara D (2007) Optimal adjuvant therapy for non-small cell lung cancer-how to handle stage I disease. Oncologist 12:331-337 (Pubitemid 46556800)
5. Wang X, Zhao J, Yang L et al (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 27:484-490
6. Yuan ZQ, Sun M, Feldman RI et al (2000) Frequent activation of AKT2 and induction of apoptos is by inhibi tion of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19:2324-2330 (Pubitemid 30307208)
7. Sun M, Wang G, Paciga JE et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431-437 (Pubitemid 32751073)
8. Altomare DA, Tanno S, De Rienzo A et al (2002) Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 87:470-476
9. LoPiccolo J, Blumenthal GM, Bernstein WB et al (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11:32-50
10. Schuurbiers OC, Kaanders JH, van der Heijden HF et al (2009) The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4:761-767
11. Murakami D, Tsujitani S, Osaki T et al (2007) Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric Cancer 10:45-51 (Pubitemid 46356263)
12. Brognard J, Clark AS, Ni Y et al (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997 (Pubitemid 32720961)
13. Clark AS,West K, Streicher S et al (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1:707-717
14. West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5:234-248 (Pubitemid 36132805)
15. Pantuck AJ, Seligson DB, Klatte T et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257-2267 (Pubitemid 46801555)
16. Akcakanat A, Sahin A, Shaye AN et al (2008) Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112:2352-2358
17. Lim WT, Zhang WH, Miller CR et al (2007) PTEN and phosphorylated AKT expression and prognosis in early-And late-stage nonsmall cell lung cancer. Oncol Rep 17:853-857
18. Balsara BR, Pei J, Mitsuuchi Y et al (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25:2053-2059 (Pubitemid 39534841)
19. Dhillon T, Mauri FA, Bellezza G et al (2010) Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 5:314-319
20. Lee S, Kim YC, Lee HM et al (2010) Prognostic value of phosphorylated Akt and survivin expression in gastric adenocarcinoma. Korean J Pathol 44:252-258
21. Travis WD BE, Muller-Hermelink HK et al (2004) World Health Organization International Histological Classification of Tumours, Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
22. Travis WD (2009) Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 54:3-11
23. Zubrod C, Scheiderman M, Frei E III et al (1960) Cancer appraisal of methods for the study of chemotherapy of cancer in men: thiophosphoramide. J Chronic Dis 11:7-33
24. Lin F, Zhang PL, Yang XJ et al (2006) Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 36:283-293 (Pubitemid 44320422)
25. Anagnostou VK, Bepler G, Syrigos KN et al (2009) High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 15:4157-4164
26. David O, Jett J, LeBeau H et al (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stageindependent survival disadvantage. Clin Cancer Res 10:6865-6871 (Pubitemid 39383035)
27. Yu P, Zhou L, KeWet al (2010) Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol 136:1283-1292
28. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91:1420-1424 (Pubitemid 39486341)
29. Massion PP, Taflan PM, Shyr Y et al (2004) Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170:1088-1094 (Pubitemid 39488621)